Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04323046 · ClinicalTrials.gov registry record · Phase 1
Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults
A Phase 1 study of Glioblastoma and Recurrent Glioblastoma, sponsored by Sabine Mueller, MD, PhD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 20
- Study locations
NCT04323046 is a Phase 1 study of Glioblastoma and Recurrent Glioblastoma that is actively recruiting participants, run by Sabine Mueller, MD, PhD. The registered enrollment target is 20 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (82% lower). The trial reports 20 study locations across 17 states.
The verdict
NCT04323046, a Phase 1 study of Glioblastoma and Recurrent Glioblastoma, is actively recruiting participants, sponsored by Sabine Mueller, MD, PhD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase I trial studies the side effects of nivolumab before and after surgery in treating children and young adults with high grade glioma that has come back (recurrent) or is increasing in scope or severity (progressive). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Conditions Studied
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Questionnaire Administration
- BIOLOGICAL Nivolumab
Study Locations (20)
California
- Children's Hospital of Los Angeles - Los Angeles
- Rady Children's Hospital - San Diego
- University of California, San Francisco - San Francisco
New South Wales
- Sydney Children's Hospital - Sydney
- The Children's Hospital at Westmead - Westmead
Alabama
- University of Alabama at Birmingham, Children's of Alabama - Birmingham
District of Columbia
- Children's National Hospital - Washington D.C.
Florida
- University of Florida - Gainesville
Indiana
- Riley Children's Hospital - Indianapolis
Maryland
- Johns Hopkins University - Baltimore
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2020-10-02 |
| Est. Completion | 2029-03-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04323046
The ClinicalTrials.gov registry entry for NCT04323046 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (82% lower). The listed sponsor is Sabine Mueller, MD, PhD, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Glioblastoma appearing as the primary indexed condition, and to 3 interventions - of which Quality-of-Life Assessment is the first listed.
NCT04323046 reports 20 study locations spanning 17 distinct geographic areas - top geographies include California, New South Wales, Alabama.
Frequently Asked Questions
What is clinical trial NCT04323046 about?
NCT04323046 is a clinical study titled "Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults". This phase I trial studies the side effects of nivolumab before and after surgery in treating children and young adults with high grade glioma that has come back (recurrent) or is increasing in scope or severity (progressive). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the...
What is the current status of trial NCT04323046?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2020-10-02. Estimated completion is 2029-03-01.
What conditions does trial NCT04323046 study?
This clinical trial studies the following conditions: Glioblastoma, Recurrent Glioblastoma, Malignant Glioma, Recurrent Malignant Glioma, Grade III Glioma.
What interventions are being tested in trial NCT04323046?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Questionnaire Administration (OTHER), Nivolumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04323046?
This trial is sponsored by Sabine Mueller, MD, PhD, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04323046 being conducted?
This trial has 20 study locations across Alabama, California, District of Columbia, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
RECRUITING · Phase 1
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
-
CUE-102 in Recurrent Glioblastoma
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.